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1.1 Lung cancer 
1.1.1 Epidemiology of lung cancer 
According to the cancer report 2019, there are 606,880 Americans would die from 
cancer, which means that nearly 1,700 deaths per day. The greatest number of 
deaths arises from cancers among men and women is lung cancer (Siegel et al. 
2019). Lung cancer is still the most common cancer and the leading cause of 
cancer direct or indirect related mortality worldwide (Brambilla and Travis 2014; 
Bray et al. 2018). The International agency for research reported more than 2 
million new lung cases (11.6 % of the total new cancer cases) and more than 1.8 
million deaths (18.4 % of the total cancer deaths) worldwide in 2018 (Figure 1) 
(Bray et al. 2018; Ferlay et al. 2019). The combined five-year survival rate for all 
stages is only 18.0 % (Siegel et al. 2018).  
 
 
Figure 1: Distribution of cases and deaths for the three most common cancers in 

























1.1.2 Classification of lung cancer 
Lung cancer is confirmed and diagnosed by a histological or cytological approach 
(Nizzoli et al. 2011; Rekhtman et al. 2011), and can be defined into two major 
types: non-small-cell lung cancer (NSCLC, 85 % of all cases) and small cell lung 
cancer (SCLC, 15 % of all cases) according to the World Health Organization 
(WHO) classification (Duruisseaux and Esteller 2018; Marx et al. 2015; Travis et 
al. 2015). This classification reflects the clinical differences among different types 
of lung cancer, including clinical manifestations, the rate of metastasis and the 
effectiveness of treatment. Moreover, NSCLCs are further subdivided into lung 
adenocarcinoma (AC) (~45.0 %) and squamous cell lung carcinoma (SQCLC) 
(~25.0 %) (Figure 2 (Politi and Herbst 2015; Skoulidis and Heymach 2019; Travis 
et al. 2015)). 
The new classification of lung cancer reflects the better understanding of the 
molecular characteristics of lung cancer and individual therapy or multi-therapy 
(Skoulidis and Heymach 2019). For example, mutations of epidermal growth 
factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) have been shown 
to be sensitive to targeted therapies such as tyrosine kinase inhibitors (Nakaoku 
et al. 2014; Shim et al. 2015; Takeuchi et al. 2012). Approximately 75.0 % of all 
lung adenocarcinoma harbor genetic alterations that lead to promote a series of 
aberrant signaling pathway such as receptor tyrosine kinase (RTK)/RAS/RAF 
axis (Cancer Genome Atlas Research 2014) (76.0 % of cases), p53 pathway 
alteration (63.0 %), and alteration of cell cycle regulators (64.0 %). These 
targetable genetic alterations hold the promise to be used as therapeutic targets. 
In SQCLC, although researches show abnormal pathway including 
phosphatidylinositol-4,5-biphosphate 3-kinase (PI(3)K), rat sarcoma (RAS) and 
RTK signaling in cancers, related targeted drugs have not been arrived clinical 
yet so far (Cancer Genome Atlas Research 2014). SCLC is the worst prognosis 
subtype. Studies have identified SOX2 and fusion RLF-MYCL1 as potential 
targets, however molecular-targeted agents has not yet been developed (Cancer 





Figure 2: Histological and molecular subtypes of NSCLC. NSCLC: non-small cell 
lung carcinoma; AC: adenocarcinoma; SQCLC: squamous cell carcinoma.  
 
1.1.3 Treatment of lung cancer 
Over the last decades, many important discoveries and efforts have been made 
to improve curative therapies and decrease the mortality of lung cancer. In 
general, surgery is still considered standard therapy for early-stage NSCLC 
(Vansteenkiste et al. 2014). However, patients with NSCLC usually present in 
advanced stages and are unresectable and require systemic treatment. Recent 
developments have highlighted molecular distinct and therapeutic vulnerabilities 
in lung cancer subtypes. These findings have led to the development of targeted 
therapies and immune checkpoint inhibitors. 
Molecular targeted therapy and immunotherapy are the most advanced 
therapeutic methods in recent years (Borghaei et al. 2015; Mok et al. 2009). 
Although these methods provide more choices and have substantially increased 
length and quality of life for some patients with lung cancer (Herbst et al. 2016; 
Kris et al. 2014), the limitations of these therapeutics are obvious. The molecular 
Molecular subtyping of AC
29.1 % KRAS
27.3 % other genes
14.2 % FGFR1/2
7.2 %  RIT1
6.3 %  EGFR
3.4 %  BRAF
3.1 %  NF1
2.6 %  MAP2K1
2.2 %  ERBB2
1.6 %  MET
0.9 %  ALK
0.8 %  RET
0.5 %  ROS1
0.5 %  HRAS
0.3 %  NRAS





Molecular subtyping of SQCLC
22 % FGFR1/2
6 %  MET
4 %  DDR2
2 %  BRAF
33 % other genes
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targeted therapy is expensive (Djalalov et al. 2014) and only effective in patients 
with specific gene mutation (Paez et al. 2004). In the same manner, only some 
patients with NSCLC benefit from immunotherapy and the effect varies from 
person to person (Garon et al. 2015; Reck et al. 2016). For patients with SCLC, 
the chemotherapy or combination with radiotherapy is the primary therapeutic 
modality on account of few advances in therapeutic options (Okamoto et al. 2007; 
Takada et al. 2002).  
Regardless of histological subtypes and stage of lung cancer, the systemic 
chemotherapy remains an essential treatment for patients with lung cancer. For 
early-stage lung cancer, it has been proved that adjuvant cisplatin based 
chemotherapy could increase improve survival time (Arriagada et al. 2010; 
Morgensztern et al. 2016; Salazar et al. 2017), and 1-year survival increases in 
patients with advanced lung cancers using chemotherapy (Paz-Ares et al. 2013; 
Sandler et al. 2006). According to the American society of clinical oncology and 
national comprehensive cancer network (NCCN) guidelines, chemotherapy 
regimens for NSCLC combine two cytotoxic agents in first-line e.g. Pemetrexed 
and cisplatin is a standard treatment combination for NSCLC (Scagliotti et al. 
2008; Schiller et al. 2002).  
Pemetrexed is a novel multi-target agent that inhibits hymidylate synthase 
(TYMS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotide 
formyltransferase (GARFT) (Adjei 2000; Shih et al. 1997). Cisplatin is a widely 
used and well-known anticancer drug, which causes deoxyribonucleic acid (DNA) 
damage, block cell division and induce apoptosis in cancer cells (Dasari and 
Tchounwou 2014). Although pemetrexed plus cisplatin shows similar efficacy 
compared to other standard treatment options, the combination of 
pemetrexed/cisplatin in patients with adenocarcinoma demonstrated a 
significantly better survival than cisplatin/gemcitabine, as well as better tolerability 
and good performance (Gadgeel et al. 2011; Paz-Ares et al. 2012; Paz-Ares et 
al. 2013; Scagliotti et al. 2014; Scagliotti et al. 2008). However, chemotherapy 
resistance is a major issue in the clinic. Some lung tumors initially response to 




1.2 One-carbon metabolism 
One-carbon metabolism is a universal metabolic cycle in health and disease and 
is composed of folate compounds chemical reactions. Furthermore, this pathway 
is important in nucleic acid synthesis, mitochondrial protein synthesis in, amino 
acid metabolism, vitamin metabolism (Ducker and Rabinowitz 2017; Shane and 
Stokstad 1985; Stipanuk 2004; Stover 2004; Tibbetts and Appling 2010). 
 
1.2.1 One-carbon metabolism in cancer  
One-carbon metabolism includes both the de novo serine synthesis pathway and 
folate cycles (Ducker and Rabinowitz 2017). First, 3-phosphoglucerate (3-PG) is 
a metabolite originated from glucose in glycolysis and can be converted into 
serine by 3-phosphoglycerate dehydrogenase (PGDH3). In addition, PGDH3 can 
regulate the release of the tetrahydrofolate (THF) into mitochondria (Fell and 
Snell 1988; Snell 1984). Subsequently, within the mitochondrial first step of folate 
cycles, the THF is converted to intermediate metabolites, 5, 10-methenylene-THF 
or 10-formyl-THF, by their enzymes (Hebbring et al. 2012; Snell et al. 1987), the 
serine methyltrasferases 2 (SHMT2), methylenetetrahydrofolate dehydrogenase 
2 (MTHFD2), separately. Then, the 10-formyl-THF from the mitochondria can be 
regenerated and converted into the 5, 10-methenylene-THF by an enzyme in the 
cytosol, MTHFD1 (Tibbetts and Appling 2010; Yang and Vousden 2016). Finally, 
some of the 5, 10-methenylene-THF is directly converted THF, the rest is involved 
in the thymidylate synthesis catalyzed by an enzyme, thymidylate synthase 
(Ducker and Rabinowitz 2017). Furthermore, these enzymes play the key role at 
maintaining a complete oxidative/reductive cycle also in cancer cells including 






Figure 3: One-carbon metabolism in cancer cells.  
 
Recent studies have identified the de-novo serine synthesis pathway, where the 
mitochondrial folate metabolism and one-carbon metabolic enzymes are 
upregulated in cancer cells (Ducker and Rabinowitz 2017; Mehrmohamadi et al. 
2014; Newman and Maddocks 2017). These metabolic enzymes play an 
important role in tumorigenesis and tumor development. 
PGDH3 is required for tumorigenesis and proliferation in melanoma and breast 
cancer cell lines (Locasale et al. 2011; Mullarky et al. 2011; Possemato et al. 
2011). Furthermore, studies showed that PGDH3 contributes to cell 
maintenance, migration and invasion in different cancer including renal cell 
carcinoma, breast cancer and pancreatic cancer (Samanta et al. 2016; Song et 
al. 2018; Yoshino et al. 2017).  
SHMT2 catalyzes mitochondrial one-carbon metabolism (Ducker and Rabinowitz 
2017; Stover and Schirch 1990), is important for tumor growth in various types of 
cancer such as melanoma, breast cancer, and ovarian carcinoma (Lee et al. 
2014) and maintains a compartmentalized one-carbon pathway in mitochondria 
(Minton et al. 2018). 
Nilsson et al. (2014) reported that MTHFD2 amplification and MTHFD2 protein 
are significantly increased in cancers such as lung cancer, breast cancer and 
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colon cancer and MTHFD2 over-expression was shown in proliferating tumors 
which enhancement growth of cancer cells related with production of excessive 
one-carbon units for purine synthesis (Christensen and Mackenzie 2008). A study 
reported that expression of MTHFD2 indicated an increased invasiveness and 
poor prognosis in cancers including breast cancer, renal cell cancer, and 
hepatocellular carcinoma (Lehtinen et al. 2013; Liu et al. 2014; Liu et al. 2016; 
Minton et al. 2018). Knockdown of MTHFD2 impaired cell proliferation and 
induced differentiation in acute myeloid leukemia (Pikman et al. 2016).  
Together, these findings have provided evidence that the one-carbon metabolism 
pathway is important for oncogenesis in several cancer entities. 
 
1.2.2 One-carbon metabolism in cancer therapy 
Recently, one-carbon metabolism has been developed a promising molecular 
target in cancer therapy (Dominguez-Salas et al. 2012; Koseki et al. 2018; 
Nilsson et al. 2014; Williams 2012). Various traditional cytotoxic 
chemotherapeutic agents, such as antifolates (e.g. Methotrexate, Pemetrexed, 
Aminopterin), have been developed to target the one-carbon metabolic pathway. 
PGDH3 has a role of serine synthesis and is associated with tumor cell 
proliferation. Inhibition of the serine synthesis pathway by specific inhibitors or 
relative RNAi highly reduces tumor cell growth (Mullarky et al. 2016; Pacold et al. 
2016). For example, targeting PGDH3 reduces breast cancer cell proliferation 
and inhibits xenograft growth specifically in cell lines with overexpression of 
PGDH3 (Pacold et al. 2016). However, PGDH3 suppression inhibited 
proliferation in human breast cancer cells even supplementation with additional 
serine in media was not able to rescue a capacity of cell growth (Chen et al. 2013; 
Possemato et al. 2011). This suggests that it may bypass the PGDH3 to provide 
serine to cancer cells by other mechanisms or pathways. Naturally, residual one-
carbon metabolism enzymes including SHMT2, MTHFD2, MTHFD1 and TYMS 
are novel potential targets for cancer treatment given their important role in 
cancer (Christensen and MacKenzie 2006; Tedeschi et al. 2015). Studies 
reported the activity of enzymes of the serine synthesis pathway is increased and 
expression of SHMTs is also uprelated in cancer cells (Snell and Weber 1986). 
5-fluorouracil (5-FU) targets TYMS which blocks availability of thymidylate, 
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inhibits DNA replication and induces apoptosis (Longley et al. 2003). Raltitrexed 
which targets TYMS is used for the treatment of advanced colorectal cancer 
(Cunningham et al. 1996; Minton et al. 2018). Pemetrexed inhibits multiple folate-
requiring enzymes that are involved in the synthesis of nucleotides, including 
TYMS, SHMTs, GARFT, and DHFR (Daidone et al. 2011; Smith et al. 2000). 
Moreover, deleterious side effects of chemotherapy drugs in healthy proliferating 
cells and chemoresistance in cancer cells are an important problem in clinical 
practice. The selective inhibition of individual one-carbon metabolism enzymes in 
cancer cells might reduce adverse side effects. 
MTHFD2 is a member of MTHFD enzyme family and necessary for nucleotide 
synthesis. MTHFD2 is widely found in embryonic, non-differentiated tissues and 
is almost exclusively expressed in cancer cells (Bolusani et al. 2011; Nilsson et 
al. 2014). One of mitochondrial folate metabolic enzymes, MTHFD2 has paid 
much attention as a potential therapeutic target (Miyo et al. 2017; Nilsson et al. 
2014; Pikman et al. 2016). For example, adding excess formate to cell cultures 
failed to rescue MTHFD2 silence cancer cells (Nilsson et al. 2014; Pikman et al. 
2016), indicating that MTHFD2 expression may be required for cell growth. 
However, with following a shift to the cytosolic one-carbon pathway, lack of 
MTHFD2 did not affect cell survival (Ducker et al. 2016). SHMT2 enzyme 
knockdown did not observe the blockage of mitochondrial pathway and induce 
cell death, whereas glycine is deleted from culture medium, SHMT2-knockdown 
was found to impair cell growth (Jain et al. 2012; Kim et al. 2015).  
Locasale et al. (2011) showed that decreasing expression of PGDH3 impaired 
proliferation in PGDH3 amplified cell lines by generating an inducible shRNA 
targeting PGDH3 which led to be blunt effects on the growth of breast cancer 
cells. Small molecule inhibitors of PGDH3 have been identified and were 
selectively toxic to cancer cell lines and successfully reduced cancer cell 
proliferation (Mullarky et al. 2016; Pacold et al. 2016). Studies demonstrated that 
high expression of SHMT2 and MTHFD2 in cancers was associated with lower 





1.3 Aims of the study 
Lung cancer is a major cause of cancer related deaths worldwide. With the 
development of molecular targeted therapy and immunotherapy, the landscape 
of lung cancer treatment has changed to combination therapy. However, 
systemic chemotherapy is still an indispensable treatment in lung cancer. 
Recent studies have demonstrated that one-carbon metabolism enzymes are 
upregulated in cancer cells. The aim of this study is to specify the role of one-
carbon metabolism in lung cancer. 
The first part of the project was to characterize the expression and prognostic 
impact of the one-carbon metabolism enzymes PGDH3, SHMT2, MTHFD2, 
MTHFD1 and TYMS by immunohistochemistry in human lung cancer samples. 
The second to evaluate one-carbon metabolism enzymes expression in human 
lung cancer cell lines.  
It has been demonstrated in many tumors that one-carbon metabolism 
enzymes promote cancer cell proliferation. Hence, RNAi-mediated silencing of 
one-carbon metabolism enzymes was analyzed in lung cancer cells. 
Finally, the changes in the cytotoxicity of cisplatin or pemetrexed agent in lung 






2 Material  
2.1 Chemicals 
Table 1: List of chemicals 
Chemicals  Manufacturer 
Clearify Clearing Agent American MasterTech, Lodi, 
California 
EnVision Flex Target Retrieval 
Solution, Ph Low (50X)  
Dako, Hamburg, Germany 
EnVision Flex Target Retrieval 
Solution, pH High (50X)  
Dako, Hamburg, Germany 
Wash Buffer Dako, Hamburg, Germany 
EnVision Flex Peroxidase-Blocking 
Reagent 
Agilent, Santa Clara, California 
EnVision Flex Substrate Buffer Agilent, Santa Clara, California 
EnVision Flex+ Mouse Linker SM804 Agilent, Santa Clara, California 
EnVision Flex+ Rabbit Linker SM805 Agilent, Santa Clara, California 
EnVision Flex/HRP Agilent, Santa Clara, California 
EnVision Flex Substrate Working 
Solution DAB+ Chromogen 
Agilent, Santa Clara, California 
Shandon Eosin Y Thermo Scientific, Waltham,  
Massachusettes 
Hematoxylin 7211 Thermo Scientific, Waltham,  
Massachusettes 
Ethanol 99 % Chemsolute, Th. Geyer GmbH & 
Co. KG, Renningen, Germany 
Xylol Chemsolute, Th. Geyer GmbH & 
Co. KG, Renningen, Germany 
Ethanol 96 % Chemsolute, Th. Geyer GmbH & Co. 
KG, Renningen, Germany 
RPMI-1640 medium Gibco, Waltham, USA 
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Chemicals  Manufacturer 
Fetal bovine serum (FBS) Gibco, Waltham, USA 
L-Glutamine Gibco, Waltham, USA 
Penicillin-Streptomycin Gibco, Waltham, USA 
0.05 %Trypsin-EDTA (1Х) Gibco, Waltham, USA 
MuseTM Count & Viability Kit Luminex, Austin, USA 
4x Laemmli Samper Buffer Bio-Rad Laboratories, Munich, 
Germany 
10x Tris/Glycine/SDS Bio-Rad Laboratories, Munich, 
Germany 
Western Lightning Plus-ECL PerkinElmer, Waltham,USA 
CellTiter 96 Aqueous One Solution 
Reagent 
Promega, Madison, Wisconsin, 
USA 
Cisplatin Hexal AG, Holzkirchen,Germany 
HiPerFect Transfection Reagent Qiagen, Hilden, Germany 
Ponceau-S Sigma-Aldrich, Munich, Germany 
Protein marker Thermo Scientific, Waltham,  
Massachusettes 
 
2.2 Primary antibodies 
Table 2: List of primary antibodies 
Antibodies Company 
Western Blotting  Immunohistochemistry 
concentration concentration pH 
PGDH3 Sigma 1:1000 1:500 6 (low) 
SHMT2 Cell signaling 1:1000 1:200 6 (low) 




Western Blotting  Immunohistochemistry 
concentration concentration pH 
     
MTHFD1 ATLAS 1:1000 1:500 6 (low) 
TYMS Abcam 1:1000 1:50 9 (high) 
PARK7 Abcam 1:1000   
 
2.3 Small interfering RNA (siRNAs) 
Table 3: List of siRNAs 
Targets Company 
All-star control siRNA Qiagen, Hilden, Germany 
PGDH3 (SI00090405) Qiagen, Hilden, Germany 
SHMT2 (SI04176501) Qiagen, Hilden, Germany 
MTHFD2 (SI02664928) Qiagen, Hilden, Germany 
MTHFD1 (SI02653084) Qiagen, Hilden, Germany 
TYMS (SI02780757) Qiagen, Hilden, Germany 
 
2.4 Equipment 
Table 4: List of equipment 
Equipment Manufacturer 
10 % SDS-PAGE Gel Bio-Rad Laboratories GmbH, Munich, 
Germany 






Heraeus flow hood Thermo, Fisher Scientific GmbH, 
Schwerte, Germany 
Standard-Incubator BINDER GmbH, Tuttlingen, Germany 
4° Refrigerator SIMENS Aktiengesellschaft, Munich, 
Germany 
-20° Refrigerator SIMENS Aktiengesellschaft, Munich, 
Germany 
Systec VX-100, Autoclave Thermo, Fisher Scientific GmbH, 
Schwerte, Germany 
Systec VE-40, Autoclave Thermo, Fisher Scientific GmbH, 
Schwerte, Germany 
GFL 1004 Water Bath GFL Gesellschaft für Labortechnik 
GmbH, Burgwedel, Germany 
Heraeus Microbiological 
Incubator B12 
Thermo, Fisher Scientific GmbH, 
Schwerte, Germany 
IKA Vibrax-VXR Orbital Shaker KA-Werke GmbH & Co. KG, Staufen, 
Germany 
IKA Vibrax-RCT basic KA-Werke GmbH & Co. KG, Staufen, 
Germany 
Sanyo MDF-592 Laboratory 
Freezer 
SANYO Electric Co., Ltd., Osaka, 
Japan 
Nalgene® Cryo 1°C Freezing 
Container 
Thermo, Fisher Scientific GmbH, 
Schwerte, Germany 
Eppendorf Centrifuge 5424  Eppendorf Vertrieb Deutschland 
GmbH, Wesseling-Berzdorf, Germany 
Eppendorf Centrifuge 5430R  Eppendorf Vertrieb Deutschland 





Eppendorf Pipettes  Eppendorf Vertrieb Deutschland 
GmbH, Wesseling-Berzdorf, Germany 
Eppendorf Centrifuge 5804  Eppendorf Vertrieb Deutschland 
GmbH, Wesseling-Berzdorf, Germany 
Eppendorf ThermoMixer comfort Eppendorf Vertrieb Deutschland 
GmbH, Wesseling-Berzdorf, Germany 
Trans-Blot® Turbo™ Transfer 
System 
Bio-Rad Laboratories GmbH, 
Feldkirchen 
Polymax 1040 Shakers & Mixers Heidolph Instruments GmbH & Co.KG, 
Schwabach, Germany 
Analytical Balance Sartorius 
Research R200D 
Sartorius AG, Göttingen, Germany 
Zeiss Axiovert 25 mycrosocpy Carl Zeiss AG, Oberkochen, Germany 
Merck's Muse Cell Analyzer Merck KGaA, Darmstadt, Germany 
Scotsman AF 80 SCOTSMAN, Milan, Italy 
Olympus BX41 Olympus Europa SE & Co. KG, 
Hamburg, Germany 
Fusion Fx Vilber Lourmat Vilber Lourmat Deutschland GmbH, 
Eberhardzell, Germany 
Pipette Tips  
 
 











2.5 Human tissues 
Approval for using patient materials and all information in this study was 
obtained from the Ethics Committee of the University Medical Center 
Goettingen (#1-2-08). All procedures were in accordance with the standards 
declaration of Helsinki and institutional, state, and federal guidelines. 
Specimens of tumor tissues were obtained from surgical resections at the 
Department of Thoracic Surgery of the University Medical Center Goettingen. 
2.6 Cell lines 
There were 16 human lung cancer cell lines in this study, which were 
purchased from American Type Culture Collection (ATCC):  
(1) AC cell lines: H1993, H2228, H3122, HCC44, HCC78, HCC827. 
(2) SQCLC cell line: HCC15, H2170, H520, EBC-1, EBC-1KRAS G12D/WT. 
(3) SCLC cell lines: DMS114, H1339, H69, H82, HCC33 
2.7 Software 
Table 5: List of software 
Software  Company 
Microsoft office Microsoft Corporation, Redmond, 
USA 
ImageJ National Institute of Health, 
Bethesda, USA 
GraphPad Prism 7 GraphPad Software, San Diego, 
USA 
MagellanTM Tecan Group Ltd., Männedorf, 
Switzerland 
i-control™ Microplate Reader 
Software 
Tecan Group Ltd., Männedorf, 
Switzerland 
ZEN 2012 (blue edition), version 
1.1.2.0 




2.8 Laboratory made solutions 
Table 6: List of buffer and solution 
Buffer and solution 
Stock lysis buffer 
 
150 mM NaCl 
50 mM Tris/HCL pH 7.6 
5 mM NaF 
1 % NP40 
Working lysis buffer  
 
10 µl Sodium orthovanadate  
40 µl Complete-EDTA 
100 µl 2 % Lauryl 
850 µl Stock lysis buffer 
10x Tris-buffered saline (TBS) 
 
4.2 g Tris 
26 g Tris-HCL 
292.4 g NaCl 
pH 7.4 with HCl 
ddH2O to 1 L 
1x Tris-buffered saline with Tween 20 
(TBST) 
 
10 ml Tween 20 
1 L 10x Tris-buffered saline 
9 L ddH2O 
Ponceau solution 0.2 g Ponceau-Rot 
3 ml Acetic acid 





3.1 Immunohistochemistry (IHC) 
The formalin-fixed and paraffin-embedded lung cancer tissues from 323 patients 
were combined into tissue microarrays (TMAs). Immunohistochemistry stainings 
were performed on a Dako Omnis advanced staining system and on the Dako 
Autostainer link 48 with the following steps: 2-μm tissue sections were immersed 
in clearing agent for one cycle of one minute and subsequently incubated in 
EnVision Flex Target Retrieval Solution, pH low or high (see Material 2.2) for 30 
min. Next, slides were incubated with the primary antibodies at room temperature 
(RT) for 30 min and blocked in EnV FLEX Peroxidase-Blocking reagent for 3 min. 
Then, slides were incubated with the secondary antibody EnVision FLEX/HRP 
for 20 min and DAB for 5 min. Finally, samples were incubated in Hematoxylin 
for 3 min for counterstaining.  
 
3.2 IHC evaluation 
The TMAs stainings were analyzed by light microscopy at 100x and 400x. 
Staining intensity of PGDH3, SHMT2, MTHFD2, MTHFD1 and TYMS in the 
cytoplasm of cancer cells was classified as follows: 0 means negative expression; 
1 means weak expression; 2 means strong expression.  
 
3.3 Cell culture 
Human lung cancer cells preserved in liquid nitrogen -196°C were thawed in a 
water bath at 37°C for 2-3 min and then transferred to sterile centrifuge tubes with 
9 ml complete culture medium, next, centrifuged at 1,200 rounds per minute 
(RPM) at RT for 5 min. The supernatant was discarded. Subsequently, cells were 
transferred in 5 ml culture medium to culture flasks. Cell lines were cultured in 
RPMI-1640 medium supplemented with 10 % fetal bovine serum (FBS), 1 % 
Penicillin/Streptomycin and 1 % L-Glutamine in a humidified atmosphere of 5 % 
CO2 at 37°C. Generally, the medium was refreshed every 48-72 h. When the cells 
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were approximately 80 % confluent, they were split at a 1:2 or 1:5 split ratio. All 
sub-cultures of cells were under 30 passages. Cultures were monitored using an 
inverted microscope to evaluate cell density and to confirm that there were no 
bacterial, fungal and mycoplasma. Adherent cell lines were harvested when cell 
confluency was close to 80 %. Old media was removed, cells were washed with 
1x PBS twice then added about 2-3 ml 0.05 % Trypsin-EDTA (1Х) for 5 min to 
trypsinize cells. Cells were re-suspended and transferred into a sterile centrifuge 
tube with 10 ml culture media. Then, after centrifuging at 1,200 RPM and RT for 
5 min, the supernatant was removed and the pellet was re-suspended by adding 
freezing medium. The vials were aliquoted to 1 ml per vial, then placed in a 
freezing container and frozen overnight at -80°C. Vials were transferred to liquid 
nitrogen for indefinite storage. 
 
3.4 Cell counting 
Cells were harvested and re-suspended in cell culture medium as described in 
the cell culture to create single-cell suspensions, and then mixed cells with 
MuseTM Count/Viability Reagent in a sample tube: 20 μl of cell suspension into 
380 μl of Count/Viability Reagent. Samples were subjected to load and run assay 
by MuseTM Cell Analyzer with Count/Viability program. 
 
3.5 Protein isolation and western blot analysis  
1-5 × 106 cells were washed twice with cold 1x PBS and collected in Eppendorf 
tubes. Afterwards, cells were lysed with lysis buffer on ice for 30 min, then 
centrifuged at 14,000 RPM, 4°C for 20 min. The supernatant was transferred to 
a new Eppendorf tube. The DCTM protein assay kit was used to determine the 
concentration of protein. Solution S was diluted 1:50 in solution A. 20 µl of this 
mixture were added to a 96-well plate. 2 µl protein lysate was added and 200 µl 
solution B was added, then incubated for 10 min at RT. The absorbance was 
measured by MagellanTM software and the concentration was calculated 
according to an internal standard curve. The protein lysates were dissolved in 4x 
Laemmli Samper buffer (dilute sample 3:1 with sample buffer) then denatured at 
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95°C for 5 min. Then equivalent protein sample (20 µg) was separated by 4-12 
% SDS-PAGE gel and electro-transferred onto polyvinylidene difluoride (PVDF) 
membrane by trans-blot turbo transfer system. The membrane was qualified with 
Ponceau-S and then blocked in 5 % fat-free milk for 1 h at RT. Subsequently, the 
membrane was incubated overnight in primary antibody (Table 2) on the shaker 
at 4°C. On the second day, the membrane was rinsed 3 times for 10-15 min at 
RT with 1x TBST and incubated with secondary antibody for 1 h on the shaker at 
RT. Next, the membrane was rinsed 3 times for 10-15 min at RT with 1x TBST. 
Capturing signal was performed on a fusion imaging system. PARK7 was used 
as internal loading control (Wisniewski and Mann 2016). A summary of primary 
antibodies used is shown in materials (2.2). 
 
3.6 Cell viability assay 
2.500 cells were plated in 96-well plates in 100 µl/well culture medium. After 
24 h of incubation the cells were treated with various concentration of cisplatin 
(0 µM, 1 µM, 5 µM, 10 µM, 50 µM, 100 µM.) for 72 h or pemetrexed (0 µM, 
0.005 µM, 0.025 µM, 0.05 µM, 0.25 µM, 0.5 µM, 2.5 µM, 5 µM, 25 µM, 50 µM) 
for 96 h. For measurements, the cells were incubated with 20 µl of CellTiter 96 
aqueous one solution reagent at 37°C, 5 % CO2 for 2 h. The 96-well plates 
were measured by i-control™ microplate reader software with the absorbance 
at 490 nm and the background absorbance at 650 nm subtracted. All 
experiments were repeated at least three times and each sample was plated 
in triplicate. The half maximal inhibitory concentration (IC50) was calculated 
using GraphPad Prim 7.0. 
 
3.7 siRNAs transfection 
Unless stated otherwise, cells were transfected with 20 nM siRNA using 
HiPerFect transfection reagent (Qiagen) according to the manufacturer's 
protocol. A summary of siRNAs used is shown in materials (2.3). 
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For cell viability assays: 1-5 × 104 cells/well were seeded into the 96-well plate 
with 175 μl culture medium. siRNAs or control siRNA were incubated in 
HiPerFect transfection reagent and culture medium without serum for 5-10 min 
at RT to allow formation of transfection complexes. 25 μl siRNA-HiPerFect 
reagent transfection complexes were added into a single well. After incubation 
for 24 h, 48 h, 72 h, 96 h, 120 h, 144 h, the 96-well plates were measured using 
CellTiter 96 aqueous one solution reagent. 
For western blot analysis 100 µl transfection medium containing 12 µl 
HiPerFect, 9.6 µl siRNA/negative control (20 nM) and 78.4 µl RPMI without 
serum was incubated at RT for 20 min and added to 1.5-6 × 105 cells in 6-well 
plate with 2.300 μl culture medium just after seeding. Cells were collected for 
protein isolation and western blot analysis was performed after incubating for 
72 h or 96 h.  
3.8 Statistical analyses 
Statistical analysis was performed using GraphPad Prim 7 and ImageJ. Overall 
survival was analyzed using Kaplan-Meier analyses, differences in survival were 
calculated by log-rank test. All cell experiments were repeated at least three times 
and data were expressed as mean ± standard error of mean (SEM). Statistical 
differences were tested by paired, two-tailed Student’s t-test. The correlation 
between one-carbon metabolism enzymes and IC50 was assessed by Pearson’s 




4.1 Expression of one-carbon metabolism enzymes in human 
lung cancer samples. 
In order to detect the expression and role of one-carbon metabolism enzymes 
(highlighted in Figure 4) in human lung cancer, formalin-fixed and paraffin-
embedded lung cancer tissues from 323 patients were assembled into tissue 
microarrays. The collection included AC (n = 103), SQCLC (n = 183) and SCLC 
(n = 37). The number of male patients (AC: n = 59 (57.3 %), SQCLC: n = 154 
(84.2 %), SCLC: n = 27 (73.0 %)) was higher than female patients (AC: n = 44 
(42.7 %), SQCLC: n = 29 (15.8 %), SCLC: n = 10 (27.0 %)). The median age (AC 
group: 67 years (range 34-85), SQCLC group: 66 years (range 42-83), SCLC 
group: 67 years (range 50-81)) was similar among these three groups. More than 
half of patients with AC (65.1 %) and SQCLC (76.5 %) showed a moderately 
differentiated disease, while all SCLC were poorly differentiated by definition 
(100.0 %). The frequency of T1 stage in AC patients was 50.0 %, 24.9 % in 
SQCLC patients, and 75.7 % in SCLC patients. The frequency of patients in with 
no lymph node metastasis (AC: 63.3 %, SQCLC: 55.6 %, SCLC: 75.0 %) was 
higher than the frequency of N1, N2 and N3 together. The median follow-up time 
was 23, 30 and 58 months for AC, SQCLC and SCLC, respectively and 201 
deaths were reported. The clinical characteristics are shown in Table 7. 
 
 
Figure 4: The one-carbon metabolism enzymes (highlighted) in cancer cells.  
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Table 7: Clinical data summary 
 
4.1.1 Expression of PGDH3 in human lung cancer samples. 
The described tissue samples of human lung cancers were 
immunohistochemically stained for PGDH3 and revealed a positive signal in the 
cytoplasma of the cancer cells. Signals were classified as either negative (Figure 
5 A), weak (Figure 5 B) or strong staining (Figure 5 C) based on signal intensity. 
As shown in figure 5 D, the expression of PGDH3 varied considerably with a weak 
Characteristic 
AC 
(n = 103) 
SQCLC 
(n = 183) 
SCLC 
(n = 37) 
Gender:    
Male (%) 59 (57.3) 154 (84.2) 27 (73.0) 
Female (%) 44 (42.7) 29 (15.8) 10 (27.0) 
Age median  
(range, years)  
67 (34-85) 66 (42-83) 65 (50-77) 
Tumor grade:    
G 1 (%) 9 (8.7) 0 (0.0) 0 (0.0) 
G 2 (%) 67 (65.1) 140 (76.5) 0 (0.0) 
G 3 (%) 27 (26.2) 43 (23.5) 37 (100.0) 
Tumor stage:    
T stage: n = 102 n = 181 n = 37 
T 1 (%) 51 (50.0) 45 (24.9) 28 (75.7) 
T 2-4 (%) 51 (50.0) 136 (75.1) 9 (24.3) 
N stage: n = 98 n = 178 n = 28 
N 0 (%) 62 (63.3) 99 (55.6) 21 (75.0) 
N 1-3 (%) 36 (36.7) 79 (44.4) 7 (25.0) 
Median follow-up 
time (range, months) 
23 (1-128) 26 (1-196) 34 (1-125) 
Reported deaths (%) 48 (46.7) 131 (71.6) 22 (59.5) 
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or strong expression in 64.7 % of AC, 91.1 % in SQCLC and 100.0 % in SCLC. 
Patients with pulmonary adenocarcinomas showed significant differences (P = 
0.036) in overall survival between negative (median survival 44 months), weak 
(median survival 35 months) and strong staining (median survival 32 months), 
while there was no significant difference in both SQCLC (P = 0.292) and SCLC 

































Figure 5: Prognostic significant of expression PGDH3 protein in lung cancer. A-D. 
Human lung cancer tissues were immunohistochemically stained to show the expression 
of PGDH3 protein: Negative expression of PGDH3 (A). Positive PGDH3 protein signal in 
the cytoplasm of cancer cells including weak staining (B) and strong staining (C) on the 
basis of signal intensity. (D) The fraction of PGDH3 expression in human lung cancer 
tissues. (E) Survival analysis using Kaplan-Meier estimate and log-rank test grouped by 
IHC score (IHC: immunohistochemistry, AC: adenocarcinoma, SQCLC: Squamous cell 
lung carcinoma, SCLC: Small cell lung cancer). 
 
4.1.2 Expression of SHMT2 in human lung cancer samples. 
As previously described for PGDH3, the expression of SHMT2 was 
immunohistochemically examined and classified as negative (Figure 6 A), weak 
(Figure 6 B) or strong staining (Figure 6 C). The expression of SHMT2 in patients 
with AC (63.3 %), SQCLC (85.9 %), SCLC (92.1 %) is shown in figure 3-3 D. 
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Kaplan-Meier analysis showed no significant differences in overall survival in 

































Figure 6: Expression of SHMT2 protein in lung cancer. A-D. Human lung cancer tissues 
were immunostained to show the expression of SHMT2 protein: Negative expression of 
SHMT2 (A). Positive SHMT2 protein signal in the cytoplasm of cancer cells including 
weak staining (B) and strong staining (C) on basis of signal intensity. (D) The fraction of 
SHMT2 expression in human lung cancer tissues. (E) Survival analysis using Kaplan-
Meier estimate and log-rank test grouped by IHC score. 
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4.1.3 Expression of MTHFD2 in human lung cancer samples. 
The expression of MTHFD2 was examined as described before and staining was 
again classified as either negative (Figure 7 A), weak (Figure 7 B) or strong 
staining (Figure 7 C). MTHFD2 protein was strongly expressed in SQCLC (81.2 
%), SCLC (81.6 %), and AC (50.0 %) (Figure 7 D). Kaplan-Meier estimation of 
overall survival of patients among negative (median survival 43 months), weak 
staining (median survival 34 months) and strong staining (median survival 23 
months) revealed a significant difference in AC (P = 0.044), but not in SQCLC 


































Figure 7: Prognostic significant of expression MTHFD2 protein in lung cancer. A-D. 
Human lung cancer tissues were immunostained to show the expression of MTHFD2 
protein: Negative expression of MTHFD2 (A). Positive MTHFD2 protein signal is brown 
particles-like distribution in the cytoplasm of cancer cells including weak staining (B) and 
strong staining (C) on basis of signal intensity. (D) The fraction of MTHFD2 expression 
in human lung cancer tissues. (E) Survival analysis using Kaplan-Meier estimate and 
log-rank test grouped by IHC score. 
 
4.1.4 Expression of MTHFD1 in human lung cancer samples. 
The same immunohistochemical analysis was performed for MTHFD1 (negative 
(Figure 8 A), weak (Figure 8 B) and strong staining (Figure 8 C)). IHC results 
showed expression of MTHFD1 in patients among AC (94.0 %), SQCLC (84.8 %) 
and SCLC (82.4 %) (Figure 8 D). Kaplan-Meier analysis showed no significantly 
difference in overall survival of patients with AC (P = 0.278), SQCLC (P = 0.984), 
or SCLC (P = 0.991) (Figure 8 E). 
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Figure 8: Expression of MTHFD1 protein in lung cancer. A-D. Human lung cancer tissues 
were immunostained to show the expression of MTHFD1 protein: Negative expression 
of MTHFD1 (A). Positive MTHFD1 protein in the cytoplasm of cancer cells including weak 
staining (B) and strong staining (C) on basis of signal intensity. (D). The fraction of 
MTHFD1 expression in human lung cancer tissues. (E). Survival analysis using Kaplan-
Meier estimate and log-rank test grouped by IHC score. 
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4.1.5 Expression of TYMS in human lung cancer samples. 
On the basis of mentioned IHC criteria, TYMS was classified as either negative 
(Figure 9 A), weak (Figure 9 B) or strong staining (Figure 9 C). Expression of 
TYMS was seen in 86.2 % of patients with AC, 80.0 % in SQCLC, and 89.2 % in 
SCLC (Figure 9 D). No significant differences in overall survival of patients with 
AC (P = 0.262), SQCLC (P = 0.349), and SCLC (P = 0.609) were obtained by 

































Figure 9: Expression of TYMS protein in lung cancer. A-D. Human lung cancer tissues 
were immunostained to show the expression of TYMS protein: Negative expression of 
TYMS (A). Positive TYMS protein signal in the cytoplasm of cancer cells including weak 
staining (B) and strong staining (C) on basis of signal intensity. (D) The fraction of TYMS 
expression in human lung cancer tissues. (E) Survival analysis using Kaplan-Meier 
estimate and log-rank test grouped by IHC score. 
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4.2 Expression of one-carbon metabolism enzymes in lung 
cancer cell lines. 
In order to investigate the function of one-carbon metabolism enzymes in human 
lung cancer, western blot analysis and cell viability assay were performed in vitro. 
Western blot analysis was used to examine the expression of one-carbon 
metabolism proteins in human lung cancer cell lines grouped by AC (n = 6), 
SQCLC (n = 5) and SCLC (n = 5) and to validate knockdown. To explore whether 
the one-carbon metabolism enzymes are associated with tumor cell proliferation, 
a cell viability assay was used to determine the cell viability by knockdown of one-
carbon metabolism enzymes through siRNAs. 
 
4.2.1 PGDH3 enzyme in human lung cancer cell lines.  
As shown in figure 10 A, western blots analysis showed a differential expression 
of PGDH3 in human lung cancer cell lines. Intensity of western blot bands were 
qualified using ImageJ and results presented in figure 10 B. The cell line with the 
highest expression quantity of PGDH3 was eighteen times higher than the lowest 
one in AC cell lines, four times higher than the lowest one in SQCLC cell lines, 
seven times than the lowest one in SCLC cell lines. Then, cells were transfected 
with siRNAs targeting PGDH3 or control siRNA for 72 h and cell lysates were 
analyzed again by western immunoblotting to verify the decreased expression of 
PGDH3 compared to control siRNA (Figure 10 C).  
Subsequently cell proliferation was assessed by cell viability assay and revealed 
that cell proliferation of all AC cell lines was significantly reduced by 70.0 % 
compared to controls at day 6 (Figure 11 A). However, cell growth did not change 
when PGDH3 was knocked down with siRNA in SQCLC cell lines (Figure 11 B) 
and SCLC cell lines (Figure 11 C). Silencing PGDH3 did thus not affect cell 





Figure 10: Expression of PGDH3 in human lung cancer cell lines. (A). Western blot 
analysis showing the expression of PGDH3 protein in AC, SQCLC and SCLC cell lines. 
PARK7 used as a loading control. Relative molecular mass in kDa shown on the left. The 
pictures are representative for three independent experiments. (B). Signal intensities of 
PGDH3 from AC, SQCLC and SCLC cell lines were normalized to PARK7 using ImageJ 
(the data are represented as mean ± SEM of three independent experiments). (C). 
Western blot analysis showing the effect of control siRNA and PGDH3 siRNA on 
expression of PGDH3 at protein lever in AC, SQCLC and SCLC cell lines after 
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Figure 11: Knockdown of PGDH3 significant reduced cell proliferation of lung AC 
cell lines. Cell viability assays showing the cell proliferation of the AC (A), SQCLC (B), 
and SCLC cell lines (C) after transfecting of siRNA against PGDH3 or control siRNA (the 
data are represented as mean ± SEM of at least three independent experiments with 
three technical replicates each, two-tailed Student’s t-test: * P < 0.05,** P < 0.01,*** P < 
0.001). 
 
4.2.2 SHMT2 enzyme in human lung cancer cell lines. 
The expression of SHMT2 protein was examined by western blot analysis 
(Figure 12 A). Intensity of western blot bands was normalized to internal 
loading control PARK7 using ImageJ software. As shown in figure 12 B, all of 
the examined cell lines expressed SHMT2 but to a various degree. Expression 
of SHMT2 in AC and SCLC cell lines was similar. The highest expression of 
SHMT2 was found in the SQCLC cell line H2170. 

















































Next, the described cell lines were transfected with siRNAs targeting SHMT2. 
Cells were incubated with SHMT2-siRNA or control siRNA for 72 h and then 
collected for cell lysis for western blot analysis. Results showed that SHMT2 
protein levels were significantly inhibited by SHMT2 siRNA compared to control 
siRNA (Figure 12 C).  
Further, cell proliferation was determined by cell viability assays. Cell 
proliferation was significantly reduced after transfecting SHMT2 siRNA for 4 
days compared to control siRNA in AC cell lines (Figure 13 A). Although cell 
proliferation of HCC15, one of SQCLC cell lines, was decreased after 
transfection with SHMT2 siRNA, the rest of SQCLC cell lines did not show 
consistent results (Figure 13 B). Moreover, there was no impact of SHMT2 






Figure 12: Expression of SHMT2 in human lung cancer cell lines. (A). Western blot 
analysis showing the expression of SHMT2 protein in AC, SQCLC and SCLC cell lines. 
PARK7 was used as loading control. Relative molecular mass in kDA is shown on the 
left. The pictures are representative of three independent experiments. (B). Signal 
intensities of SHMT2 from AC, SQCLC and SCLC cell lines were normalized to PARK7 
using ImageJ (the data are represented as mean ± SEM of three independent 
experiments). (C). Western blot analysis showing the effect of control siRNA and SHMT2 






































































H2228 H3122 HCC44 HCC78 HCC827
+        -
- +
+        -
- +
+        -
- +
+        -
- +
+        -
- +
+   - +     - +     - +   - +       -
- +       - +      - +       - +       - +     
HCC15     H2170      H520      EBC-1    EBC KRAS
+   - +     - +     - +   - +       -
DMS114    H1339     H69            H82       HCC33
























































































































































































Figure 13: Knockdown of SHMT2 significant reduced cell proliferation of lung AC 
cell lines. Cell viability assays showing the cell proliferation of the AC (A), SQCLC (B) 
,SCLC cell lines (C) after transfecting of siRNA against SHMT2 or control siRNA (the 
data are represented as mean ± SEM of at least three independent experiments with 
three technical replicates each, two-tailed Student’s t-test: * P < 0.05,** P < 0.01,*** P < 
0.001). 
 
4.2.3 MTHFD2 enzyme in human lung cancer cell lines. 
We detected MTHFD2 expression by western blot analysis (Figure 14 A), which 
showed strong expression in AC, SQCLC and SCLC cell lines. To determine 
the expression quantity of MTHFD2 protein, western blot bands of MTHFD2 
protein were normalized to internal loading control PARK7 and results were 
shown in figure 14 B. All described cell lines expressed MTHFD2 protein. The 
AC cell line with the highest MTHFD2 protein level was HCC44. The SQCLC 
cell line with the highest MTHFD2 level was H2170. The lowest MTHFD2 
protein level was found in the SCLC cell line H1339. Expression of MTHFD2 
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protein in the remaining cell lines was in a similar range. Next, cells were 
transfected with siRNAs targeting MTHFD2 for 96 h. Western blot analysis 
showed that MTHFD2 protein was significantly reduced compared to controls 
(Figure 14 C).  
Subsequently, cell viability assay revealed that cell proliferation was 
significantly inhibited upon MTHFD2 knockdown starting from day 3 or day 4 
and decreased by 50.0 % after 6 days in all AC (Figure 15 A) and SQCLC cell 
lines (Figure 15 B). However, cell proliferation was inhibited in only 3 of 5 SCLC 






Figure 14: Expression of MTHFD2 in human lung cancer cell lines. (A). Western blot 
analysis showing the expression of MTHFD2 protein in AC, SQCLC and SCLC cell lines. 
PARK7 was used as loading control. Relative molecular mass in kDa is shown on the 
left. The pictures are representative for three independent experiments. (B). Signal 
intensities of MTHFD2 from AC, SQCLC and SCLC cell lines were normalized to PARK7 
using ImageJ (the data are represented as mean ± SEM of three independent 
experiments). (C). Western blot analysis showing the effect of control siRNA and 
MTHFD2 siRNA on expression of MTHFD2 at protein lever in AC, SQCLC and SCLC 
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Figure 15: Knockdown of MTHFD2 significant reduced cell proliferation of lung 
cancer cell lines. Cell viability assays showing the cell proliferation of the AC (A), 
SQCLC (B) ,SCLC cell lines (C) after transfecting of siRNA against MTHFD2 or control 
siRNA (the data are represented as mean ± SEM of at least three independent 
experiments with three technical replicates each, two-tailed Student’s t-test: * P < 0.05,** 
P < 0.01,*** P < 0.001). 
 
4.2.4 MTHFD1 enzyme in human lung cancer cell lines. 
In figure 16 A, western blot analysis revealed that MTHFD1 protein was 
abundantly expressed in AC, SQCLC and SCLC cell lines. Western blot bands 
displayed the highest expression of MTHFD1 protein in the SQCLC cell line 
H2170. The other SQCLC, AC, and SCLC cell lines showed similar MTHFD1 
protein levels (Figure 16 B). Next, cells were transfected with MTHFD1 siRNA 
or control siRNA for 96 h. As shown in figure 16 C, MTHFD1 siRNA clearly 
inhibited the expression of MTHFD1 protein in both AC and SQCLC cell lines 
but not in all SCLC cell lines compared to control siRNA.  
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Furthermore, cell viability assays were performed to detect cell proliferation 
after treatment with MTHFD1 siRNA or control siRNA. AC cell lines treated with 
MTHFD1 siRNA, showed dramatic growth arrest (Figure 17 A). Particularly the 
proliferation of HCC44 cells was significantly inhibited from day 2. SQCLC cell 
lines showed similar changes and cell proliferation was significantly decreased 
after transfection with MTHFD1 siRNA (Figure 17 B). Among SQCLC cell lines, 
HCC15 was outstanding, since the proliferation was strongly decreased from 
day 2 after treatment with MTHFD1 siRNA. Consistent with western blot 
analysis results, not all SCLC cell lines showed response to MTHFD1 siRNA 
(Figure 17 C). Cell proliferation of DMS114, H1339 and H69 cell line was 






Figure 16: Expression of MTHFD1 in human lung cancer cell lines. (A). Western blot 
analysis showing the expression of MTHFD1 protein in AC, SQCLC and SCLC cell lines. 
PARK7 used as loading control. Relative molecular mass in kDa is shown on the left. 
The pictures are representative of three independent experiments. (B). Signal intensities 
of MTHFD1 from AC, SQCLC and SCLC cell lines were normalized to PARK7 using 
ImageJ (the data are represented as mean ± SEM of three independent experiments). 
(C). Western blot analysis showing the effect of control siRNA and MTHFD1 siRNA on 
expression of MTHFD1 at protein lever in AC, SQCLC and SCLC cell lines after 
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Figure 17: Knockdown of MTHFD1 significant reduced cell proliferation of lung 
cancer cell lines. Cell viability assays showing the cell proliferation of the AC (A), 
SQCLC (B) ,SCLC cell lines (C) after transfecting of siRNA against MTHFD1 or control 
siRNA (the data are represented as mean ± SEM of at least three independent 
experiments with three technical replicates each, two-tailed Student’s t-test: * P < 0.05,** 
P < 0.01,*** P < 0.001). 
 
4.2.5 TYMS enzyme in human lung cancer cell lines. 
Western blot analysis indicated that TYMS protein was widely expressed in AC, 
SQCLC and SCLC cell lines (Figure 18 A). ImageJ software was used to 
normalize the western blot bands and results were presented in figure 18 B. 
TYMS protein was expressed in all human lung cancer cell lines but in various 
degree. Among AC cell lines, HCC44 and H2228 were the two with the highest 
expression. Among SCLC cell lines, H82 and HCC33 were the two with the 
highest expression. TYMS protein expression in the SQCLC cell line H520 was 
higher than all other human lung cancer cell lines. Next, all cell lines were 
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transfected with TYMS siRNA or control siRNA for 96 h, western blot analysis 
were performed to verify TYMS protein expression was remarkably decreased 
by TYMS siRNA in comparison to control siRNA (Figure 18 C).  
Furthermore, cell proliferation was accessed using cell viability assay. Cells 
were seeded in 96 well plates and treated with TYMS siRNA or control siRNA. 
Cell proliferation of all AC cell lines was severely inhibited by TYMS siRNA 
starting from day 3 or day 4 in comparison to control siRNA and decreased to 
50.0 % at day 6 (Figure 19 A). Cell proliferation of SQCLC cell lines HCC15 
and EBC-1 was significantly decreased from day 3 to less than 50.0 % at day 
6. Cell proliferation of the EBC-1 KRAS G12D/WT cell line was significantly 
inhibited from day 5 and by 50.0 % at day 6. TYMS siRNA showed no impact 
on the remaining SQCLC cell lines (Figure 19 B). In SCLC cell lines, only cell 
proliferation of the DMS114 and H1339 cell line was significantly inhibited to 






Figure 18: Expression of TYMS in human lung cancer cell lines. (A). Western blot 
analysis showing the expression of TYMS protein in AC, SQCLC and SCLC cell lines. 
PARK7 used as loading control. Relative molecular mass in kDa is shown on the left. 
The pictures are representative of three independent experiments. (B). Signal intensities 
of TYMS from AC, SQCLC and SCLC cell lines were normalized to PARK7 using ImageJ 
(the data are represented as mean ± SEM of three independent experiments). (C). 
Western blot analysis showing the effect of control siRNA and TYMS siRNA on 
expression of TYMS at protein lever in AC, SQCLC and SCLC cell lines after transfecting 
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Figure 19: Knockdown of TYMS significant reduced cell proliferation of lung 
cancer cell lines. Cell viability assays showing the cell proliferation of the AC (A), 
SQCLC (B), SCLC cell lines (C) after transfecting of siRNA against TYMS or control 
siRNA (the data are represented as mean ± SEM of at least three independent 
experiments with three technical replicates each, two-tailed Student’s t-test: * P < 0.05,** 
P < 0.01,*** P < 0.001). 
 
4.3 Association between one-carbon metabolism enzymes 
and cytotoxic responsiveness to cisplatin and pemetrexed 
in human lung cancer cell lines 
Chemotherapy is the basic treatment for patients with lung cancer. Cisplatin 
and pemetrexed are the first-line medications. As we found that expression of 
one-carbon metabolism enzymes correlated with overall survival for patients 
with lung cancer, we further investigated the correlation between one-carbon 
metabolism enzymes and cytotoxic responsiveness to cisplatin and 
pemetrexed in human lung cancer cell lines. Cell viability assays were 
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performed to evaluate the effects of cisplatin and pemetrexed on the viability 
of AC, SQCLC and SCLC cell lines. The IC50 for cisplatin and pemetrexed 
were calculated on the basis of dose-response curves. Afterwards, correlation 
analysis was used to investigate the relationship between the expression of 
one-carbon metabolism proteins and IC50 values of cisplatin and pemetrexed 
in AC, SQCLC and SCLC cell lines. 
 
4.3.1 Correlation of one-carbon metabolism proteins expression with 
cisplatin or pemetrexed sensitivity in human AC cell lines. 
To evaluate the sensitivity of AC cell lines to cisplatin or pemetrexed treatment, 
the IC50 of cisplatin or pemetrexed was calculated from dose-response curves 
in all of the six described AC cell lines. As shown in figure 20 A and B, both 
agents reduced the cell viability in AC cell lines. The IC50 values for cisplatin 
ranged from 3.01 μM to 12.84 μM and for pemetrexed from 0.03 μM to 184.20 
μM (Table 8). HCC44 and HCC827 showed the strongest resistance to 
pemetrexed (Figure 20 B). Even at the highest concentration (50 μM), 
pemetrexed only inhibited HCC44 and HCC827 cell viability by less than 5.0 % 
whereas cisplatin decreased cell viability by 80.0 % at 5 μM. HCC78 and H1993 
showed the best response to pemetrexed (Figure 20 B). Cell viability 
decreased to less than 50.0 % at 0.05 μM. 
Afterwards, we performed a Pearson’s correlation analysis of one-carbon 
metabolism proteins expression with drug sensitivity in these lines and 
revealed that expression of MTHFD2 significantly and reciprocally correlated 
with pemetrexed resistance, with a Pearson coefficient of r = 0.871 (P = 0.024, 
Figure 20 D), indicating that the expression of MTHFD2 protein was associated 
with pemetrexed resistance in lung AC cell lines. However, correlation between 
the expression of MTHFD2 and IC50 of cisplatin was not significant (Figure 20 
C). Moreover, there were no correlation between expression of PGDH3, 
SHMT2, MTHFD1, TYMS the and IC50 of cisplatin and pemetrexed (Figure 20 




Table 8: IC50 values of cisplatin and pemetrexed in AC cell lines 
 Drugs 
 Cisplatin (μM) Pemetrexed (μM) 
 IC50 95% CI * IC50 95% CI 
H1993 12.84 (11.03-14.96) 0.10 (0.03-0.38) 
H2228 3.28 (2.27-4.68) 0.42 (0.08-6.90) 
H3122 10.70 (9.37-12.22) 0.28 (0.09-1.01) 
HCC44 1.88 (1.56-2.26) 184.20 (116.20-354.60) 
HCC78 3.01 (2.12-4.25) 0.03 (0.01-0.06) 
HCC827 10.76 (7.50-15.62) 158.5 (95.65-326.70) 





















































































































































Figure 20: Correlation of one-carbon metabolism proteins expression with 
cisplatin or pemetrexed sensitivity in AC cell lines. Inhibitory dose-response curves 
for AC cell lines treated with cisplatin (A) for 72 h and pemetrexed (B) for 96 h are shown. 
The dots and bars represent as mean ± SEM of at least three independent experiments 
with three technical replicates each. (C and D). Pearson’s correlation analyses of one-
carbon metabolism protein expression with drug sensitivity are shown. Correlation 
curves show the correlation between the IC50 values of cisplatin (C) and pemetrexed 
(D) and the expression of one-carbon metabolism proteins in relation to loading control 
as obtained by western blot analysis. 
 
4.3.2 Correlation of one-carbon metabolism proteins expression with 
cisplatin or pemetrexed sensitivity in human SQCLC cell lines. 
To evaluate the sensitivity of SQCLC cell lines to cisplatin or pemetrexed 
treatment, the IC50 of cisplatin or pemetrexed was calculated from dose-
response curves in all of the five described SQCLC cell lines. All SQCLC cell 
lines showed good response to cisplatin (Figure 21 A) but were resistant 
against pemetrexed (Figure 21 B). Cisplatin significantly inhibited cell viability 
of all SQCLC cell lines by 80.0 %, pemetrexed only inhibited cell viability by 
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less than 50.0 % except for H520. The IC50 values of cisplatin and pemetrexed 
in SQCLC cell lines were calculated and represented in table 9 on the basis of 
dose-response curves: the IC50 values of cisplatin ranged from 4.41 μM to 
23.98 μM and from 1.62 μM to 70.79 μM for pemetrexed. There was no 
correlation between one-carbon metabolism protein expression and drug 
sensitivity by Pearson’s correlation analysis in SQCLC cells (Figure 21 C, D). 
 
Table 9: IC50 values of cisplatin and pemetrexed in SQCLC cell lines 
 Drugs 
 Cisplatin (μM) Pemetrexed (μM) 
 IC50 95% CI * IC50 95% CI 
HCC15 23.98 (18.33-31.40) 70.79 (35.07-170.40) 
H2170 4.41 (3.87-5.02) 59.98 (24.76-179.10) 
H520 11.21 (9.08-13.87) 1.624 (0.82-3.23) 
EBC-1 27.26 (24.17-30.73) 30.66 (8.51-89.73) 
EBC-1KRASG12D/WT 16.53 (11.33-24.37) 28.35 (8.59-77.65) 













































































































































Figure 21: The expression of one-carbon metabolism protein is not associated 
with chemoresistance in SQCLC cell lines. Inhibitory dose-repose curves show the 
SQCLC cell lines treated with cisplatin (A) for 72 h and pemetrexed (B) for 96 h. The dots 
and bars represent the mean ± SEM of at least three independent experiments, each 
with three technical replicates. Correlation curves show the correlation between the IC50 
values of cisplatin (C) and pemetrexed (D) and the expression of one-carbon metabolism 
proteins in SQCLC cell lines. 
 
4.3.3 Correlation of one-carbon metabolism proteins expression with 
cisplatin or pemetrexed sensitivity in human SCLC cell lines. 
To evaluate the sensitivity of SCLC cell lines to cisplatin or pemetrexed treatment, 
the IC50 of cisplatin or pemetrexed was calculated from dose-response curves in 
all of the five described SQCLC cell lines. Cell viability of SCLC cell lines was 
strongly inhibited by treatment of cisplatin except H69 (Figure 22 A). Cisplatin 
inhibited cell viability of H69 by only 40.0 % even at the highest concentration 
(100 μM). SCLC cell lines showed resistance to pemetrexed (Figure 22 B), 
although DMS114 could be inhibited by 60.0 % at the highest concentration of 
pemetrexed (50 μM). The IC50 values of cisplatin and pemetrexed were 
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calculated and shown in table 10 according to dose-response curves: the IC50 of 
cisplatin ranged from 2.96 μM to 15.58 μM and from 0.22 μM to 65.66 μM for 
pemetrexed. Subsequently, we used a Pearson’s correlation analysis and found 
that expression of SHMT2 significantly and reciprocally correlated with cisplatin 
resistance (r = 0.926, P = 0.024) (Figure 22 C). However, we did not observe a 
significant correlation between one-carbon metabolism proteins expression and 
the response to pemetrexed in SCLC cell lines (Figure 22 D). 
 
Table 10: IC50 values of cisplatin and pemetrexed in SCLC cell lines 
 Drugs 
 Cisplatin (μM) Pemetrexed (μM) 
 IC50 95% CI * IC50 95% CI 
DMS114 6.79 (5.64-8.17) 0.22 (0.10-0.50) 
H1339 2.96 (2.44-3.57) 4.02 (0.82-21.46) 
H69 53.73 (20.00-132.20) 47.31 (16.84-147.80) 
H82 3.70 (2.24-5.91) 58.39 (23.33-188.50) 
HCC33 15.58 (12.10-20.17) 65.66 (32.04-157.40) 














































































































































Figure 22: Correlation of one-carbon metabolism proteins expression with 
cisplatin or pemetrexed sensitivity in SCLC cell lines. Inhibitory dose-repose curves 
show the SCLC cell lines treated with cisplatin (A) for 72 h and pemetrexed (B) for 96 h. 
The dots and bars represent the mean ± SEM of at least three independent experiments, 
each with three technical replicates. Correlation curves show the correlation between the 
IC50 values of cisplatin (C) and pemetrexed (D) and the expression of one-carbon 
metabolism proteins in SCLC cell lines. 
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5 Discussion  
The hyperproliferation of cancer cells commonly points to a high requirement 
on one-carbon metabolism, which could be developed as anticancer target. For 
example, the anti-folate drug aminopterin was already used successfully for 
acute lymphoblastic leukemia (ALL) in children in 1948 (Farber and Diamond 
1948). Today, chemical variants of driven folate antagonists chemotherapeutic 
agents and are used to treat several cancer types by FDA approving (Locasale 
2013) including lung cancer, ALL, breast cancer, bladder cancer and 
lymphomas (Chabner and Roberts 2005; Locasale 2013; Vander Heiden 
2011).  
A study pointed that the capacity of cell growth and proliferation is associated 
with cancer cells reprogram one-carbon metabolism (Boroughs and 
Deberardinis 2015). For example, PGDH3, the rate-limiting enzyme for serine 
synthesis, has been implicated in multiple cancers such as breast cancer, 
melanomas and NSCLC tumors (Denicola et al. 2015; Locasale et al. 2011; 
Maddocks et al. 2013; Possemato et al. 2011; Zhang et al. 2017). MTHFD2, a 
crucial enzyme in mitochondrial metabolism, indicated with a poor prognosis in 
breast cancer (Jain et al. 2012), hepatocellular carcinoma (Liu et al. 2016), 
pancreatic cancer (Noguchi et al. 2018) and a study showed that abolishment 
of MTHFD in vitro strongly inhibits remote metastasis of melanoma cells 
(Piskounova et al. 2015).  
Hence, we first assessed the expression of one-carbon enzyme proteins by 
immunohistochemistry in human lung cancer specimens and showed that 
MTHFD2 and PGDH3 were strongly expressed in the three major lung cancer 
subtypes AC, SQCLC, and SCLC. Furthermore, MTHFD2 and PGDH3 
expression were correlated with poor prognosis in patients with pulmonary 
adenocarcinoma, supporting previous studies in human pancreatic cancer, 
breast cancer, hepatocellular carcinoma (Liu et al. 2014; Liu et al. 2016; Song 
et al. 2018). Interestingly, although positive MTHFD2 staining was more 
frequent in SQCLC (81.2 %) and SCLC (81.6 %) than in AC cases (50.0 %), 
there was no correlation with prognosis in patients with SQCLC or SCLC. 
Surprisingly, residual one-carbon metabolic marks were not associated with 
overall survival in three subtypes of lung cancer.  
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Given that MTHFD2 within mitochondrial one-carbon metabolism can catalyze 
the NAD+ dependent reactions (Tibbetts and Appling 2010). The folate cycle 
directly produces the nicotinamide adenine dinucleotide phosphate hydrogen 
and also it intersects with the methionine cycle to contribute product of 
glutathione (Maddocks et al. 2013).  
In addition, several studies showed that enzymes level of the folate cycle 
correlate with oncogenes such as KRAS, MYC. For example, upregulation of 
the folate metabolism enzyme MTHFD2 in NSCLC cells with KRAS-mutant 
may be found a higher anti-folate activity (Moran et al. 2014). A report showed 
mTORC1, stimulating the mTHF cycle, provides one-carbon units to MTHFD2 
to promote a production of purine nucleotides and contribute to affect cell 
growth (Ben-Sahra et al. 2016).  
To study the expression and function of one-carbon metabolism enzymes in 
vitro, we used sixteen human lung cancer cell lines (six AC, five SQCLC and 
five SCLC) which recapitulate the histological classification. We analyzed the 
sensitivity of the three lung cancer subtypes to pemetrexed. Pemetrexed, is a 
novel anti-folate agent which inhibits THF cofactor-dependent enzymes, and is 
approved for the treatment of lung cancer and selected for some solid tumors 
like breast cancer (Chattopadhyay et al. 2007). As expected, our findings 
revealed that MTHFD2 expression in AC cell lines was correlated with 
sensitivity to pemetrexed. It is evident that the MTHFD2 result obtained here 
was in exceptionally good agreement with existing studies that gefitinib 
resistance depended on MTHFD2-mediated mitochondrial one carbon 
metabolism (Nishimura et al. 2019). Although MTHFD2 was markedly 
expressed in SQCLC and SCLC cell lines, there were no association between 
MTHFD2 protein levels and sensitivity to pemetrexed. This suggested that cell 
survival of AC cell lines may be particularly dependent on mitochondrial folate 
metabolism enzymes. 
Additional, SHMT2, another mitochondrial one-carbon metabolism enzyme 
that is frequently overexpressed in lung cancer produces catalytically the 
glycine (Nilsson et al. 2014) which acts as substrate for MTHFD2 in one-carbon 
cycle. Accumulating evidence showed that SHMT2 expression is significantly 
increased in cancers such as ovarian cancer, breast cancer, colorectal cancer 
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and correlates with poor prognosis (Lee et al. 2014; Wang et al. 2017; Zhang 
et al. 2016). SHMT2 in vitro knockdown was associated with a reduction of cell 
proliferation and an inhibition of tumorigenicity in hepatocellular cancer cell 
lines (Woo et al. 2016). A synergistic effect of MTHFD2 (mitochondrial) and 
SHMT1 (cytosolic) in inhibiting colorectal carcinoma growth in vivo (Ducker et 
al. 2016) has been shown. However, we did not detect any correlation between 
SHMT2 expression and IC50 of pemetrexed in AC cell lines. Zhang et al. 
(2012) showed that glycine decarboxylases, such as PSAT1, PSPH, and 
SHMT1 and 2 do not significantly promote glycine uptake but promote 
glycolysis instead in NIH/3T3 cells with ectopic expression of SHMT, indicating 
a synergism between one-carbon metabolism and other metabolic pathways.  
Cisplatin, an inhibitor of nucleotide metabolism and a well-known 
chemotherapeutic drug in various tumors, leads to death of cancer cells by 
interfering with the biosynthesis of cytidine, inhibition of ribonucleotide 
reductase (RNR) and preventing the formation of deoxynucleotides damaging 
DNA (Jamieson and Lippard 1999; Nilsson et al. 2014; Zamble and Lippard 
1995). Hence, we also evaluated the relationship of one-carbon metabolism 
enzymes with the response to cisplatin but did not find any correlation in the 
tested cell lines. 
Next, we used small interfering RNAs against PGDH3, SHMT2, MTHFD2, 
MTHFD1 and TYMS to study the impact of these enzymes on cell proliferation. 
We demonstrated the MTHFD2 gene strongly influenced cell proliferation in 
lung cancer. As described in the results section, cell proliferation decreased by 
50.0 % in all AC and SQCLC cell lines and in 3 of 5 SCLC cell lines upon 
knockdown of MTHFD2. Moreover, it was observed in colon cancer and 
glioblastomas that cell proliferation and survival depend on MTHFD2 
(Gustafsson et al. 2015; Nilsson et al. 2014).  
Recent research revealed that MTHFD2 enhanced malignancy and distant 
metastasis by regulation of redox homeostasis under various stress stimuli 
such as hypoxia and degradation of stroma in colorectal cancer (Ju et al. 2018). 
MTHFD2 expression is also elevated in colorectal cancer (CRC) and correlates 
with a poor prognosis (Gustafsson et al. 2017). Specifically, the first inhibitor of 
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MTHFD2 LY345899 significantly inhibits the colorectal cancer growth, 
promising a potential therapeutic agent for CRC treatment (Ju et al. 2018). 
However, the regulatory mechanism of MTHFD2 in lung cancer cells is not yet 
clear. First, the MTHFD2 enzyme is necessary for the production of NADPH 
and it has been reported that disrupting of NADPH homeostasis enhances 
drug-induced apoptosis (Ju et al. 2017). For example, inhibition of serine-
glycine biosynthesis by depletion of glutamine or PGDH3 induced apoptosis in 
EWS cells (Sen et al. 2018). It is well-known that SHMT2 is an important 
enzyme which regulates serine metabolism in mitochondria. SHMT2 
knockdown produces auxotrophic effects for glycine (Zhang et al. 2012). 
Ju et al. (2018) reported that MTHFD2 in CRC was transcriptionally 
upregulated by the oncogene cellular myelocytomatosis oncogen (c-Myc) 
rather than K-RAS downstream. MYC is a proto-typical oncogene which 
activates cell growth and proliferation, genes involved in the expression of 
metabolic enzymes from phosphoribosyl pyrophosphate (PRPP) to adenosine 
monophosphate and guanosine monophosphate in tumor-initiating cells (Wang 
et al. 2017) and purine and pyrimidine nucleotides biosynthesis along with 
inactivate apoptotic pathway (Liu et al. 2008; Pelengaris et al. 1999; Shchors 
et al. 2006). The RAS family encoding small enzymes that hydrolyze guanosine 
triphosphate belongs to the most frequently mutated group of genes in NSCLC 
(30.0 % of pulmonary adenocarcinomas (Ding et al. 2008) and 5.0 % of 
squamous cell carcinomas) (Downward 2003). These tumors carry an 
activating RAS mutation leading to constitutive activation of the RAS-ERK 
signaling pathway as an essential driver of proliferation, differentiation and 
cellular survival. Although direct inhibition of oncogenic RAS remains to be 
challenging in the future, MTHFD2 combining the first K-RAS inhibitor AMG 
510 may be of interest as a potential therapeutic strategy.  
One hypothesis is that silencing of MTHFD2 results in blockade of the cell cycle 
in adenocarcinoma cells. In support of this idea, MTHFD1 concentrated in the 
nucleus preferentially ensure to conserve thymidylate synthesis by consume 
other intermediate such as homocysteine in the cytoplasm lack of folate 
deficiency or during the cell arrest (Field et al. 2014). For example, Knockdown 
MTHFD1 with a specific RNA caused a strong decreased thymidylate 
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synthesis, on the other side, and increased uracil integration into DNA (Field et 
al. 2015). Moreover, aberrant MTHFD2 in colorectal cancer cells not only 
promoted cell proliferation, migratory and also affected cell death (Wei et al. 
2019). Serine is partiality catabolized to pyrimidine and glutathione in a group 
of AC with high expression of PGDH3 (Piskounova et al. 2015). In order to 
produce RNA and DNA, proliferating cells by upregulating pyrimidine and 
purine metabolism supply a competent substrate (Field et al. 2014). Elevated 
generation of pyrimidines and purines is required for cell division. 
Cells without p53 failed to the respond to serine depletion and cell cycle arrest 
preventing uncontrolled proliferation (Maddocks et al. 2013). The activated p53 
regulated the serine biosynthesis through reducing PGDH3 protein and 
resulting serine deprivation (Maddocks et al. 2013). The p53 mutations cause 
serine metabolism alteration that induced a strong decreased tumor growth in 
many tumors including lung cancer (Maddocks et al. 2013). Non-genotoxic 
stress activated the p53 suppress the PGDH3 protein expression, leading to 
enhancement of apoptosis in normal cells.(Kruiswijk et al. 2015). So, it is 
interesting that activation of p53 by serine starvation causes cell cycle arrest. 
Cell survival may be due to the serine cycle intersecting with glutathione 
synthesis cycle within cells (Kruiswijk et al. 2015; Maddocks et al. 2013).  
In the present study, we also examined the expression of PGDH3, MTHFD1 
and TYMS enzymes in human lung cancer cell lines, the correlation between 
expression of these enzymes and IC50 of pemetrexed or cisplatin, and cell 
proliferation after knockdown of these genes. The results did not reveal that 
expression of PGHD3, MTHFD1 or TYMS was associated with IC50 of 





In the present study, we investigated the role of one-carbon metabolism 
enzymes in human lung cancer.  
First, we measured the expression and prognostic impact of the one-carbon 
metabolism enzymes PGDH3, SHMT2, MTHFD2, MTHFD1 and TYMS in 
human lung cancer samples using IHC and found that overexpression of 
PGDH3 and MTHFD2 is marker of poor prognosis in patients with AC. Next, 
we performed experiments to investigate the function of these enzymes in lung 
cancer cell lines including AC, SQCLC and SCLC cells. Our results showed 
that knockdown of these genes significantly reduced cellular proliferation in AC 
cell lines but not in most SQCLC and SCLC cell lines. Expression of MTHFD2 
protein is positively correlated with IC50 of pemetrexed in AC cell lines. 
Altogether, the phenotypes we found supported that one-carbon metabolism 
enzymes promote proliferation of human lung cancer cells, especially in AC.  
Overall, our study revealed the diversity of one-carbon metabolism in three 
different subtypes of lung cancer. Specifically, MTHFD2 was identified as an 
independent prognostic factor and the most promising anticancer target in 
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